ATC Group: J07B Viral vaccines

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J07B in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J07 Vaccines
3 J07B Viral vaccines

Group J07B contents

Code Title
J07BA Encephalitis vaccines
J07BB Influenza vaccines
J07BC Hepatitis vaccines
J07BD Measles vaccines
J07BE Mumps vaccines
J07BF Poliomyelitis vaccines
J07BG Rabies vaccines
J07BH Rota virus diarrhea vaccines
J07BJ Rubella vaccines
J07BK Varicella zoster vaccines
J07BL Yellow fever vaccines
J07BM Papillomavirus vaccines
J07BN Covid-19 vaccines
J07BX Other viral vaccines

Active ingredients in J07B

Active Ingredient Description
Dengue vaccine
Ebola vaccine

Ebola vaccine consists of a live, attenuated recombinant vesicular stomatitis virus-based vector expressing the envelope glycoprotein gene of Zaire Ebola virus (rVSV∆G-ZEBOV-GP). Immunisation of subjects with the vaccine results in an immune response and protection from Zaire Ebola Virus Disease (EVD).

Encephalitis, tick borne

Encephalitis, tick borne suspension for injection is indicated for the active (prophylactic) immunization of persons of 16 years of age and older against tick-borne encephalitis (TBE). Its pharmacodynamic effect consists of the induction of a sufficiently high concentration of anti-TBE antibody to provide protection against the TBE virus.

Hepatitis A, inactivated vaccine

Inactivated virus of a strain which was originally derived by further serial passage of a proven attenuated strain. The virus is grown, harvested, highly purified, formalin inactivated, and then adsorbed onto amorphous aluminum hydroxyphosphate sulphate.

Hepatitis B, purified antigen

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.

Influenza, inactivated, split virus
Influenza, inactivated, whole virus
Influenza, live attenuated
Japanese encephalitis, live attenuated

Japanese encephalitis is a disease caused by the mosquito-borne Japanese encephalitis virus (JEV). Japanese Encephalitis Vaccine acts by inducing antibodies that neutralize live JEV.

L1 protein of human papillomavirus type 11
L1 protein of human papillomavirus type 16
L1 protein of human papillomavirus type 18
L1 protein of human papillomavirus type 31
L1 protein of human papillomavirus type 33
L1 protein of human papillomavirus type 45
L1 protein of human papillomavirus type 52
L1 protein of human papillomavirus type 58
L1 protein of human papillomavirus type 6
Measles, live attenuated
mRNA-1273

mRNA-1273 is COVID-19 mRNA encapsulated in lipid nanoparticles. The mRNA encodes for the full-length SARS-CoV-2 spike protein modified with 2 proline substitutions within the heptad repeat 1 domain (S-2P) to stabilise the spike protein into a prefusion conformation. After intramuscular injection, cells at the injection site and the draining lymph nodes take up the lipid nanoparticle, effectively delivering the mRNA sequence into cells for translation into viral protein. The delivered mRNA does not enter the cellular nucleus or interact with the genome, is nonreplicating, and is expressed transiently mainly by dendritic cells and subcapsular sinus macrophages. The expressed, membrane-bound spike protein of SARS-CoV-2 is then recognised by immune cells as a foreign antigen. This elicits both T-cell and B-cell responses to generate neutralising antibodies, which may contribute to protection against COVID-19.

Mumps, live attenuated
Poliomyelitis, serotype 1
Poliomyelitis, serotype 2
Poliomyelitis, serotype 3
Rabies vaccine
Rota virus

Rotavirus vaccine is indicated for the active immunisation of infants aged 6 to 24 weeks for prevention of gastroenteritis due to rotavirus infection. In clinical trials, efficacy was demonstrated against gastro-enteritis due to rotavirus of the most common genotypes G1P [8], G2P [4], G3P [8], G4P [8] and G9P [8].

Rota virus, type G1
Rota virus, type G2
Rota virus, type G3
Rota virus, type G4
Rota virus, type P1(8)
RSV glycoprotein F antigen

RSV glycoprotein F antigen is designed to enhance antigen-specific cellular immune response and neutralizing antibodies response in individuals with pre-existing immunity against RSV. The adjuvant AS01E facilitates the recruitment and activation of antigen presenting cells carrying vaccine-derived antigens in the draining lymph node, which in turn leads to the generation of RSVPreF3-specific CD4+ T cells.

Rubella, live attenuated

Rubella virus vaccine contains live attenuated rubella virus, produced in human diploid (MRC-5) cells. It is a virus vaccine for active immunization against rubella that is subcutaneously administered.

SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S)

SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is a monovalent vaccine composed of a recombinant, replicationincompetent human adenovirus type 26 vector that encodes a SARS-CoV-2 full-length spike (S) glycoprotein in a stabilised conformation. Following administration, the S glycoprotein of SARSCoV-2 is transiently expressed, stimulating both neutralising and other functional S-specific antibodies, as well as cellular immune responses directed against the S antigen, which may contribute to protection against COVID-19.

SARS-CoV-2 spike glycoprotein (B.1 strains)
SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector encoding the S glycoprotein of SARS-CoV-2. The SARS-CoV-2 S immunogen in the vaccine is expressed in the trimeric pre-fusion conformation; the coding sequence has not been modified in order to stabilise the expressed S-protein in the pre-fusion conformation. Following administration, the S glycoprotein of SARS-CoV-2 is expressed locally stimulating neutralising antibody and cellular immune responses, which may contribute to protection to COVID-19.

Smallpox, live attenuated

Smallpox vaccine is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.

Tozinameran

The nucleoside-modified messenger RNA in COVID-19 mRNA Vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19 disease.

Varicella, live attenuated

Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity.

Yellow fever, live attenuated
Zorecimeran
Attenuated varicella-zoster virus

Varicella-zoster virus vaccine was shown to boost VZV-specific immunity, which is thought to be the mechanism by which it protects against zoster and its complications.

Related product monographs

Title Information Source Document Type  
ABRYSVO Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ACAM2000 Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
ADJUPANRIX Emulsion for injection European Medicines Agency (EU) MPI, EU: SmPC
AMBIRIX Suspension for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
AREXVY Powder for suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
AVAXIM Suspension for injection in a prefilled syringe Υπουργείο Υγείας (CY) MPI, EU: SmPC
BIMERVAX Emulsion for injection European Medicines Agency (EU) MPI, EU: SmPC
COMIRNATY Concentrate for dispersion for injection European Medicines Agency (EU) MPI, EU: SmPC
COVID-19 mRNA VACCINE BNT162b2 Concentrate for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ENGERIX-B Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
ERVEBO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
FENDRIX Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
FLUAD TETRA Suspension for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
FOCETRIA Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
GARDASIL 9 Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
HBVAXPRO Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
HEPLISAV B Solution for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
IMVAMUNE Suspension for injection Health Products and Food Branch (CA) MPI, CA: SPM
IMVANEX Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
IXIARO Japanese Encephalitis Vaccine FDA, National Drug Code (US) MPI, US: SPL/PLR
JCOVDEN Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
JYNNEOS Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
MODERNA COVID-19 VACCINE CX-024414 Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
MVABEA Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
NUVAXOVID Dispersion for injection European Medicines Agency (EU) MPI, EU: SmPC
PFIZER-BIONTECH COVID-19 VACCINE BNT162b2 Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
QDENGA Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
RABIPUR Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
RECOMBIVAX HB Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
ROTARIX Powder and solvent for oral suspension European Medicines Agency (EU) MPI, EU: SmPC
SHINGRIX Powder for suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
SPIKEVAX Dispersion for injection European Medicines Agency (EU) MPI, EU: SmPC
STAMARIL Powder and solvent for suspension for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TICOVAC Suspension for injection in a pre-filled syringe Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VAQTA ADULT Suspension for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VAQTA PAEDIATRIC Suspension for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VARILRIX Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VAXZEVRIA Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
VIDPREVTYN BETA Solution and emulsion for emulsion for injection European Medicines Agency (EU) MPI, EU: SmPC
YF-VAX Powder for suspension FDA, National Drug Code (US) MPI, US: SPL/Old
ZOSTAVAX Powder and solvent for suspension for injection European Medicines Agency (EU) MPI, EU: SmPC